Global Peptic Ulcer Drugs Market - Forecast To 2030

Peptic Ulcer Drugs Market Information, by Pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others), by Clinical Application (gastric ulcers, duodenal ulcer, esophageal ulcer) - Forecast Till 2030

ID: MRFR/Pharma/1812-HCR | December 2022 | Region: Global | 85 Pages         

Peptic Ulcer Drugs Market Speak to Analyst Request a Free Sample

Market Synopsis of Peptic Ulcer Drugs Market: Market Scenario: The peptic ulcer drugs market is anticipated to reach USD 5,752.5 Million by 2030 at 4.8% CAGR during the forecast period 2022-2030. Peptic ulcer drugs are used to treat erosion of the gastrointestinal lining due to a variety of factors. Peptic ulcer is the result of an imbalance between aggressive and defensive fluids in the stomach. Peptic ulcer includes gastric, esophageal and duodenal ulcer. 

The major driving factors for petic ulcers drug market are stress, drug induced ulcers, growing rate of infection by H.Pyrroli, changes in food, rise in cancer, tobacco and alcohol use. Constraining factors of this market are patent expiry, comparatively good treatment regimen of proton pump inhibitors, resistance of H.Pyroli, extreme market fragmentation into many companies and great penetration of generics.

Study Objectives Peptic Ulcer Drugs Market:



  • To provide detail analysis of the market structure along with forecast for the next 5years of various segments and sub-segments of the peptic ulcer drugs market.

  • To provide an insight about factors affecting the Peptic Ulcer Drugs Market growth.

  • To analyze the market based on various analyses which includes price analysis, supply chain analysis, Porters Five Force analysis etc.

  • To provide past and estimated future revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future prospective.

  • To provide country level analysis of the market for segments such as by pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others) and by clinical application (gastric ulcers, duodenal ulcer, esophageal ulcer)

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape of the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research & developments globally.


Peptic Ulcer Drugs Market, by Region 2015 & 2022 (USD million): Global Peptic Ulcer Drugs Market

Intended Audience:



  • Global peptic ulcer drugs manufacturers

  • Global peptic ulcer drugs suppliers

  • Research and development Laboratories

  • Market research and consulting service providers


Key Players :


Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. Helicure AB and Eumedica Pharmaceuticals

Segments:

Peptic ulcer drugs market has been segmented on the basis of pharmacological class (proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others), by clinical application (gastric ulcers, duodenal ulcer, esophageal ulcer) and region.

Regional Analysis of Peptic Ulcer Drugs Market:


Globally North America is the largest market of peptic ulcer drugs. Europe is the second largest market for peptic ulcer drugs. Soon the market of peptic ulcer drugs will be dominated by developing regions particularly Asia Pacific which will be the fastest growing region.


The report of  Peptic Ulcer Drugs Market by Market Research Future comprises extensive primary research along with detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insights of the market and industry performance. The report gives a clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies used by  top key players in the industry. The report also gives a broad study of the different market segments and regions.



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The global peptic ulcer drugs market is projected grow at approximately 4.8% CAGR during the assessment period (2022-2030).

The valuation of the global peptic ulcer drugs market is estimated to increase to USD 5,752.5 Million by the end of 2030.

Rising prevalence of the condition and emergence of breakthrough medicines are major drivers of the global peptic ulcer drugs market.

North America holds the largest share in the global peptic ulcer drugs market, followed by Europe and the Asia Pacific, respectively.

Daiichi Sankyo Company Limited, Novartis AG, Acetelion Ltd., Sanofi S.A., Boehringer Ingelheim, Astra Zeneca plc, Takeda Pharmaceuticals Company Limited, Ranbaxy Laboratories Limited, Inc., Pfizer Inc., Eumedica Pharmaceuticals, and Helicure AB, are some of the major players operating in the peptic ulcer drugs market.